Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

NCT07523282 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune Disease
Systemic Lupus Erythematosus
Systemic Sclerosis (SSc)

Interventions

DRUG: HN2302 Injection

Sponsor

Shenzhen MagicRNA Biotechnology Co., Ltd

Collaborators

[object Object]